Ebola Post-Exposure Prophylaxis Trial Begins in DRC and Uganda

A clinical trial has commenced in the Democratic Republic of Congo and Uganda to test the antiviral obeldesivir as a post-exposure prophylaxis for the Bundibugyo Ebola virus. This initiative comes as the region faces an ongoing outbreak, declared a public health emergency, which has already led to significant infections and fatalities. The trial aims to evaluate the drug's effectiveness in protecting individuals at high risk of contracting the virus.